MedTrace Logo

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

NCT02663518 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 249

Last updated 2024-05-10

Study results available
· View outcomes & findings →

Summary

Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.

Conditions

Interventions

DRUG

PF-0791800 (TTI-621)

Monotherapy

DRUG

PF-07901800 (TTI-621) plus Rituximab

Combination therapy

DRUG

PF-07901800 (TTI-621) plus Nivolumab

Combination therapy

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-28
Primary Completion
2022-11-23
Completion
2022-11-23

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02663518 on ClinicalTrials.gov